...
首页> 外文期刊>European Journal of Surgical Oncology: The Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology >Metastatic lymph node ratio in stage III rectal cancer; prognostic significance in addition to the 7th edition of the TNM classification.
【24h】

Metastatic lymph node ratio in stage III rectal cancer; prognostic significance in addition to the 7th edition of the TNM classification.

机译:III期直肠癌的转移性淋巴结比率;除了第7版TNM分类外,对预后也有重要意义。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

AIMS: Optimal staging in rectal cancer is indispensable for the decision on further treatment and estimation of prognosis. This study assesses the prognostic capacity of the metastatic lymph node ratio (LNR) in addition to the new TNM classification. METHODS: LNR was determined, in stage III patients from the Dutch TME-trial. Six year median follow up data from the trial database were used to analyse the relation of LNR to overall survival (OS) and local recurrence (LR). The relation of LNR to lymph node yield was assessed and appropriate cut off values of LNR for clinical use were determined. RESULTS: 605 patients were analyzed. 278 underwent pre-operative radiotherapy. 82 patients developed a local recurrence and 289 distant metastases. LNR was an independent risk factor for OS, hazard ratio (HR) 2.10 (95% CI 1.35-3.27) (in addition to age >= 65 years, involved circumferential resection margin (CRM) and new TNM stage) and LR, HR 2.25 (95% CI 1.02-4.56) (in addition to pre-operative radiotherapy and involved CRM). LNR is predictive of OS and LR from a lymph node yield of more than one and more than five respectively. A LNR value of 0.60 offers the best cut off to identify high risk patients (5-years OS was 61 vs. 32%, HR 2.45 (95% CI 1.96-3.08) and 5-years LR rate 12.6 versus 16.3%, HR 1.65 (95% CI 1.03-2.64)). CONCLUSIONS: LNR is an independent risk factor for OS and LR in addition to the 7th edition of the TNM classification. It can aid in predicting prognosis and identifying patients that should be considered for adjuvant treatment.
机译:目的:直肠癌的最佳分期对于进一步治疗和评估预后至关重要。除新的TNM分类外,该研究还评估了转移性淋巴结比率(LNR)的预后能力。方法:在荷兰TME试验的III期患者中确定了LNR。来自试验数据库的六年中位数随访数据用于分析LNR与总生存期(OS)和局部复发(LR)的关系。评估LNR与淋巴结产量的关系,并确定适合临床使用的LNR临界值。结果:对605例患者进行了分析。 278接受了术前放疗。 82例患者出现局部复发和289个远处转移。 LNR是OS,危险比(HR)2.10(95%CI 1.35-3.27)(年龄大于等于65岁,涉及环切缘(CRM)和新的TNM分期)和LR,HR 2.25的独立危险因素。 (95%CI 1.02-4.56)(除术前放疗外,还涉及CRM)。 LNR通过分别超过1个和5个以上的淋巴结产量来预测OS和LR。 LNR值为0.60提供了最佳的识别高危患者的门槛(5年OS为61 vs.32%,HR 2.45(95%CI 1.96-3.08)和5年LR率为12.6 vs 16.3%,HR 1.65 (95%CI 1.03-2.64)。结论:除了TNM分类的第7版,LNR是OS和LR的独立危险因素。它可以帮助预测预后并确定应考虑进行辅助治疗的患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号